Puma Biotechnology (PBYI) Competitors

Puma Biotechnology (NASDAQ:PBYI) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Does the media prefer PBYI or ADMA?

In the previous week, ADMA Biologics had 3 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for ADMA Biologics and 2 mentions for Puma Biotechnology. ADMA Biologics' average media sentiment score of 1.27 beat Puma Biotechnology's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Puma Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of PBYI or ADMA?

61.3% of Puma Biotechnology shares are owned by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are owned by institutional investors. 23.3% of Puma Biotechnology shares are owned by company insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has higher earnings & valuation, PBYI or ADMA?

ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Puma Biotechnology	$230.50M	0.77	$30.28M	$0.77	4.66
ADMA Biologics	$426.45M	9.97	$197.67M	$0.85	20.95

Which has more risk and volatility, PBYI or ADMA?

Puma Biotechnology has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, indicating that its share price is 57% less volatile than the S&P 500.

Do analysts recommend PBYI or ADMA?

Puma Biotechnology currently has a consensus target price of $7.00, suggesting a potential upside of 94.99%. ADMA Biologics has a consensus target price of $27.67, suggesting a potential upside of 55.34%. Given Puma Biotechnology's higher possible upside, equities research analysts clearly believe Puma Biotechnology is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Puma Biotechnology	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.33

Is PBYI or ADMA more profitable?

ADMA Biologics has a net margin of 45.01% compared to Puma Biotechnology's net margin of 16.37%. Puma Biotechnology's return on equity of 49.35% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Puma Biotechnology	16.37%	49.35%	18.25%
ADMA Biologics	45.01%	47.16%	30.51%

Summary

ADMA Biologics beats Puma Biotechnology on 13 of the 17 factors compared between the two stocks.